Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Savolitinib - AstraZeneca/HUTCHMED

Drug Profile

Savolitinib - AstraZeneca/HUTCHMED

Alternative Names: AZD-6094; HMP-504; HMPL-504; Orpathys; Volitinib; Voressa

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; HUTCHMED; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Renal cell carcinoma
  • Phase II Colorectal cancer; Gastric cancer; Oesophageal cancer; Prostate cancer
  • No development reported CNS cancer; Solid tumours

Most Recent Events

  • 01 Mar 2024 AstraZeneca suspendes the phase II SOUND trial in Non-small cell lung cancer (Combination therapy, In adults, In children, In adolescents, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) due to sponsor's decision to evaluate risks and benefits of the study (NCT05374603)
  • 28 Feb 2024 Registered for Non-small cell lung cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Macau (PO)
  • 28 Feb 2024 HUTCHMED in collaboration with AstraZeneca announces intention to submit new drug application (NDA) to US FDA for Non small cell lung cancer in tne first quarter of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top